Current role of statins in the treatment of essential hypertension

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2635-2650

  Kostapanos, Michael S ^a   Milionis, Haralampos J ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Blood pressure lowering; Hyperlipidemia; Hypertension; Statin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; NITRIC OXIDE; PLACEBO; PRAVASTATIN; RENIN; ROSUVASTATIN; SIMVASTATIN; SODIUM;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DAHL SALT SENSITIVE RAT; DISEASE MODEL; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FUNCTION; LOW FAT DIET; MEDLINE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN EXPRESSION; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM METABOLISM; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION;

EID: 78049390903     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.491512     Document Type: Review

References (90)

1. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Renal function, cardiovascular disease risk factors' prevalence and 5-year disease incidence; the role of diet, exercise, lipids and inflammation markers: the ATTICA study. QJM
2. Halperin RO, Sesso HD, Ma J, et al. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006;47(1):45-50
3. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007;9(3):175-83
4. Muntner P, He J, Roccella EJ, Whelton PK. The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension 2002;39(4):897-902
5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78
6. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906
7. Pedrinelli R, Esposti ED, Dell'Omo G. LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis 2005;180(1):137-43
8. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22(6):1123-31
9. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007;29(7):1403-14
10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207
11. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7
13. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004;64(Suppl 2):43-60
14. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288(23):2998- 3007
15. Mangat S, Agarwal S, Rosendorff C. Do statins lower blood pressure? J Cardiovasc Pharmacol Ther 2007;12(2):112-23
16. Milionis HJ, Liberopoulos EN, Achimastos A, et al. Statins: another class of antihypertensive agents? J Hum Hypertens 2006;20(5):320-35
17. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007;49(4):792-8
18. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23(5):729-36
19. Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol 2006;21(4):316-21
20. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103(9):1245-9
21. Langille DB, Joffres MR, MacPherson KM, et al. Prevalence of risk factors for cardiovascular disease in Canadians 55 to 74 years ofage: results from the Canadian Heart Health Surveys, 1986-1992. CMAJ 1999;161(Suppl 8):S3-9
22. Asmar R Effect ofantihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am J Cardiovasc Drugs 2001;1(5):387-97
23. Meaume S, Rudnichi A, Lynch A, et al. Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years old. J Hypertens 2001;19(5):871-7
24. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39(6):1020-5
25. Kontopoulos AG, Athyros VG, Pehlivanidis AN, et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003;19(1):22-7
26. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002;16(10):705-10
27. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003;93(9):e98-103
28. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995;25(6):1135-43
29. Haynes WG, Hand MF, Johnstone HA, et al. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994;94(4):1359-64
30. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reduc-tase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101(12):2711-9
31. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34(6):1281-6
32. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99(25):3227-33
33. Gottsater A, Anwaar I, Lind P, et al. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis 1999;10(3):133-40
34. Moosmang S, Schulla V, Welling A, et al. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J 2003;22(22):6027-34
35. Kansui Y, Fujii K, Goto K, et al. Chronic fluvastatin treatment alters vascular contraction by inhibiting the Rho/Rho-kinase pathway. Clin Exp Pharmacol Physiol 2006;33(8):673-8
36. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002;323(1):17-24
37. Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100(21):2131-4
38. van der Linde NA, Sijbrands EJ, Boomsma F, van den Meiracker AH. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 2006;47(6):1125-30
39. Ide H, Fujiya S, Aanuma Y, Agishi Y. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990;12(5):410-20
40. Soma M, Manku MS, Horrobin DF. The effects of hydrogenated coconut oil, safflower oil, and evening primrose oil on development of hypertension and sodium handling in spontaneously hypertensive rats. Can J Physiol Pharmacol 1985;63(4):325-30
41. Rubattu S, Volpe M, Enea I, et al. Influence of hypercholesterolemia on adrenal steroid metabolism and electrolyte balance in spontaneously hypertensive rats. Endocrinology 1993;133(5):2015-21
42. Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004;148(4):635-40
43. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009;4(1):E4-9
44. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13(5):541-50
45. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30(4):968-74
46. Kishi T, Hirooka Y, Mukai Y, et al. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003;21(2):379-86
47. Ge CJ, Hu SJ, Wu YS, Chen NY. Effects of atorvastatin on vascular remodeling in spontaneously hypertensive rats. J Zhejiang Univ Sci 2003;4(5):612-5
48. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003;42(6):1091-7
49. O'Donnell MP, Kasiske BL, Katz SA, et al. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992;20(5):651-8
50. Wilson TW, Alonso-Galicia M, Roman RJ. Effects oflipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998;31(1 Pt2):225-31
51. Park JK, Mervaala EM, Muller DN, et al. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertens 2009;27(3):599-605
52. Cui W, Matsuno K, Iwata K, et al. NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models. J Pharmacol Sci 2009;111(3):260-8
53. Carnicer R, Navarro MA, Guillen N, et al. Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I. Naunyn Schmiedebergs Arch Pharmacol 2008;377(1):35-43
54. Hartner A, Klanke B, Cordasic N, et al. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate- salt hypertension. J Hypertens 2009;27(2):376-85
55. Sung BH, Izzo JL Jr, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997;10(6):592-9
56. Leibovitz E, Hazanov N, Zimlichman R, et al. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001;14(11 Pt 1):1096-8
57. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008;168(7):721-7
58. Borghi C, Dormi A, Veronesi M, et al. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella heart study. Am Heart J 2004;148(2):285-92
59. Kool M, Lustermans F, Kragten H, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995;48(3-4):217-23
60. Antonicelli R, Onorato G, Pagelli P, et al. Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther 1990;12(2):165-71
61. Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997;130(1-2):179-82
62. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005;46(3):310-5
63. Kuklinska AM, Mroczko B, Musial WJ, et al. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients: an open, pilot study. Blood Press
64. Kanbay M, Yildirir A, Bozbas H, et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 2005;27(3):297-303
65. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz Med Wochenschr 1998;128(7):272-7
66. Prandin MG, Cicero AF, Dormi A, et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise. Nutr Metab Cardiovasc Dis 2009
67. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33(2):719-25
68. Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004;6(12):742-6
69. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995;75(8):582-6
70. Kushiro T, Mizuno K, Nakaya N, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 2009;53(2):135-41
71. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 1993;71(1):82-7
72. Sinski M, Lewandowski J, Ciarka A, et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 2009;67(6):613-20
73. Kawano H, Yano K. Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment. Circ J 2006;70(9):1116-21
74. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83(10):1497-9, A8
75. Ikeda T, Sakurai J, Nakayama D, et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004;17(6):502-6
76. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35(4):549-55
77. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003;63(1):360-4
78. Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005;19(2):103-9
79. O'Callaghan CJ, Krum H, Conway EL, et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994;3(6):404-6
80. Paulsen L, Holst LM, Bech JN, et al. Glomerular filtration rate and blood pressure are unchanged by increased sodium intake in atorvastatin-treated healthy men. Scand J Clin Lab Invest 2009;69(3):323-9
81. Paulsen L, Holm C, Bech JN, et al. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans. Nephrol Dial Transplant 2008;23(5):1556-61
82. Gomes ME, Lenders JW, Bellersen L, et al. Sympathoinhibitory effect of statins in chronic heart failure. Clin Auton Res 2009;20(2):73-8
83. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18(11):781-8
84. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18(6):308-47
85. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15(12):MS1-5
86. Gryglewski RJ, Uracz W, Swies J, et al. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann NY Acad Sci 2001;947:229-45; discussion 45-6
87. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95(2):473-8
88. Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000;2(4):370-7
89. Rizos CV, Milionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther 2010; 32(3):492-505
90. Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25(8):1995-2005